The Lasting Impact of IL-2: Approaching 50 Years of Advancing Immune Tolerance, Cancer Immunotherapies, and Autoimmune Diseases.

Saved in:
Bibliographic Details
Title: The Lasting Impact of IL-2: Approaching 50 Years of Advancing Immune Tolerance, Cancer Immunotherapies, and Autoimmune Diseases.
Authors: Paul P; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Choong C; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Heinemann J; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Al-Hallaf R; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Agha Z; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Ganatra S; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Abdulrahman L; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Sinha A; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Kumar H; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Nourbakhsh B; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Hamad ARA; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Source: Immunological investigations [Immunol Invest] 2025 Jul; Vol. 54 (5), pp. 589-603. Date of Electronic Publication: 2025 Mar 17.
Publication Type: Journal Article; Review
Journal Info: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8504629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-4311 (Electronic) Linking ISSN: 08820139 NLM ISO Abbreviation: Immunol Invest Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1532-4311
DOI:10.1080/08820139.2025.2479609